Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556892 | 0.78 | GPR35 (0.57) | — | |
| SCHEMBL29406926 | 0.78 | ESR2 (0.44) | ERN1 | |
| SCHEMBL831073 | 0.75 | ERN1 (0.67) | ERN1 | |
| SCHEMBL15783651 | 0.75 | XDH (0.71) | ERN1XDH | |
| SCHEMBL29441809 | 0.75 | ERN1 (0.67) | ERN1 | |
| SCHEMBL13639933 | 0.74 | ERN1 (0.50) | ERN1 | |
| SCHEMBL10013940 | 0.73 | GPR35 (0.69) | ERN1 | |
| SCHEMBL928630 | 0.73 | ERN1 (1.00) | ERN1XDH | |
| SCHEMBL11210616 | 0.73 | ERN1 (0.65) | ERN1 | |
| SCHEMBL31730320 | 0.73 | ERN1 (0.65) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2155643-B1 | IRE-1A INHIBITORS | MANNKIND CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| EP-2520561-B1 | IRE-1A Inhibitors | MANNKIND CORP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9241942-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-9241942-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2532643-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2520561-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2008154484-A1 | IRE-1A INHIBITORS | MANNKIND CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885XDH 3389/4885 |
| US-20160168116-A1 | IRE-1alpha Inhibitors | XBP1, DDIT3, ERN1 | ERN1 3/4885XDH 3389/4885 |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885XDH 3389/4885 |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885XDH 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.